On Jun 29, 2018 Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL) Shorts Rose By 9.18%

June 29, 2018 - By Joshua Cleveland

It was reported an increase on Zealand Pharma A/S – American Depositary Shares (NASDAQ:ZEAL)’s shares shorted with 9.18%. FINRA announced shares shorted of ZEAL’s total 254,500 shares. That’s 9.18% up from 233,100 shares. With Average volume 6,100, ZEAL’s previous position will take 42 days to restore. 1.1% is Zealand Pharma A/S – American Depositary Shares float short.

ZEAL hit $13 during the last trading session after $0.07 change.Zealand Pharma A/S has volume of 3,000 shares. Since June 29, 2017 ZEAL has 0.00% and is . The stock underperformed the S&P 500 by 12.57%.

Zealand Pharma A/S, a biotechnology company, engages in the discovery, design, and development of peptide therapeutics medicines in Denmark.The firm is worth $424.62 million. It has a portfolio of proprietary medicines in late-stage clinical development focusing on gastrointestinal and metabolic diseases.Last it reported negative earnings. The firm markets lixisenatide for the treatment of type 2 diabetes under the brand names of Adlyxin and Lyxumia; and a combination of lixisenatide and insulin glargine for the treatment of type 2 diabetes under the brand names of Soliqua 100/33 and Suliqua.

Another two news for Zealand Pharma A/S (NASDAQ:ZEAL) were recently brought out by: Seekingalpha.com on June 11, 2018 with title “Your Daily Pharma Scoop: Zealand Dips, Eloxx Surges, Venetoclax Approved”. The other Streetinsider.com‘s article was titled “Zealand Pharma (ZEAL) Phase 3 Trial of Dasiglucagon Met Primary and Secondary Objectives” and brought out on June 08, 2018.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.